From Routine Testing to Model-Driven Analytical Workflows in Modern Laboratories

Pharmaceutical development is steadily shifting toward faster, more efficient analytical strategies that streamline workflows while lowering time, cost, and resource demands across both research and commercial environments. The emphasis is increasingly on automated, data-centric manufacturing supported by real-time monitoring, reducing reliance on traditional end-point quality testing. AI, automation, digital platforms, and predictive modeling are enabling a move away from trial-and-error experimentation by improving accuracy and reducing the need for extensive material and solvent use. Practical changes include replacing some UPLC analyses with NIR spectroscopy, adopting non-animal methods for microbiological testing, and applying in-silico models to anticipate dissolution behavior with fewer laboratory experiments. Collectively, these advances are reshaping analytical laboratories by accelerating processes, improving sustainability, and preserving the rigor required for regulatory assurance.

Koen Vanhoutte of Johnson & Johnson Innovative Medicine concludes his four-part interview with his opinions on what the shift from routine testing to model‑based analytical science means in in practical terms for today’s analytical laboratories.

View Additional Commentary by Koen Vanhoutte:

Beyond Trial-and-Error: Self-Optimizing LC Workflows
The Evolving Role of Chromatography in Model-Based Analytical Science
Balancing In-Silico Retention Predictions with Experimental Chromatography Confidence

Koen Vanhoutte is an Executive Director in pharmaceutical research and development with more than 25 years of industrial experience in analytical chemistry. He holds a Ph.D. in chemistry from the University of Antwerp, with his early scientific training and core expertise rooted in liquid chromatography–mass spectrometry (LC‑MS) and chromatographic method development. Over the course of his career, he has built extensive experience in Chemistry, Manufacturing and Controls (CMC) across both early‑ and late‑stage pharmaceutical development. He currently leads the Synthetics Analytical Development organization within Johnson & Johnson Innovative Medicine, where he is responsible for defining and delivering analytical strategies across the full product lifecycle, from development through commercial manufacture. His scope includes method development, validation, technology transfer, clinical trial material release, and ICH stability testing for synthetic therapeutics. His involvement in biologics is focused specifically on microbiology‑based analytical methods, and he has extensive experience supporting global regulatory submissions and inspections, including interactions with FDA and EMA. Dr. Vanhoutte is passionate about leading and developing global teams and fostering scientific excellence through people development. He is strongly committed to applying rigorous analytical science to advance therapeutic development, while staying closely connected to evolving analytical methodologies through pragmatic, applied innovation.